These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39373732)

  • 21. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study.
    Liao Y; Tan Y; Li Y; Ma F; Wang J; Zhang P; Li Q; Li Q; Luo Y; Lan B; Chen S; Xu B; Jiang H; Zhao W; Fan Y
    Heliyon; 2024 Oct; 10(19):e38147. PubMed ID: 39386840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Alvarez A; Bernal AM; Anampa J
    Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients.
    Kubeczko M; Gabryś D; Krzywon A; Jarząb M
    Br J Radiol; 2024 Oct; 97(1162):1627-1635. PubMed ID: 39120877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
    Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
    Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
    Kimmick G; Pilehvari A; You W; Bonilla G; Anderson R
    Breast Cancer Res Treat; 2024 Nov; 208(2):263-273. PubMed ID: 38922546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.
    Brandão M; Maurer C; Ziegelmann PK; Pondé NF; Ferreira A; Martel S; Piccart M; de Azambuja E; Debiasi M; Lambertini M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.
    Shao Y; Luo Z; Yu Y; Chen Q; He Y; Liu C; Nie B; Zhu F; Liu H
    Front Endocrinol (Lausanne); 2022; 13():1000704. PubMed ID: 36060981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
    Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study.
    Caliskan Yildirim E; Atag E; Coban E; Umit Unal O; Celebi A; Keser M; Uzun M; Keskinkilic M; Tanrikulu Simsek E; Sari M; Yavuzsen T
    Breast; 2023 Aug; 70():56-62. PubMed ID: 37343321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
    Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
    Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trastuzumab deruxtecan
    Zhu Y; Liu K; Zhu X; Qin Q; Zhu H
    Front Pharmacol; 2022; 13():1025243. PubMed ID: 36386213
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
    Dajsakdipon T; Susiriwatananont T; Wongkraisri C; Ithimakin S; Parinyanitikul N; Supavavej A; Dechaphunkul A; Sunpaweravong P; Neesanun S; Akewanlop C; Dejthevaporn T;
    BMC Cancer; 2024 Aug; 24(1):1018. PubMed ID: 39152401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
    Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
    JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
    Engler T; Fasching PA; Lüftner D; Hartkopf AD; Müller V; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Wallwiener M; Beckmann MW; Hein A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Kurbacher CM; Wuerstlein R; Untch M; Taran FA; Enzinger HM; Krabisch P; Welslau M; Maasberg M; Hempel D; Lux MP; Michel LL; Janni W; Wallwiener D; Brucker SY; Fehm TN; Schneeweiss A
    Geburtshilfe Frauenheilkd; 2022 Oct; 82(10):1055-1067. PubMed ID: 36186151
    [No Abstract]   [Full Text] [Related]  

  • 40. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.